Details of the Drug Reposition

General Information of This Drug (ID: DMNZBRY)

• Drug Name: Capreomycin (DMNZBRY)
• Synonyms: Capreomycin Sulfate Standard; Capreomycin sulphate; Caprocin (Disulfate); Ogostal (Disulfate); (3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(6R)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide; (3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(6R)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-methyl-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide
• Therapeutic Class: Antibiotics
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

2 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Bacterial infection	DIS5QJ9S	1A00-1C4Z	Approved	[1]
Pulmonary tuberculosis	DIS6FLUM	1B10.Z	Approved	[2]

1 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Mycobacterium infection	DISNSMUD	1B10-1B21	Phase 2	[3]

References

• [1] Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
• [2] Capreomycin FDA Label
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015